Targeting signal transduction for disease therapy

Medical Oncology

Volumn 14, Issue 2, 1997, Pages 83-89

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Disease therapy; Epidermal growth factor; Platelet derived growth factor; Targetting signal transduction

Indexed keywords

ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; ALPHA (3,5 DICHLOROBENZYLIDENE) 3 PYRIDYLACETONITRILE; CD19 ANTIGEN; CELL NUCLEUS RECEPTOR; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; GENISTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TYRPHOSTIN;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL CYCLE; HUMAN; HUMAN CELL; ONCOGENE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; SIGNAL TRANSDUCTION;

EID: 0030813014     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02990952     Document Type: Article

References (63)

1. Levitzki, A. (1994) Signal transduction therapy. Eur. J. Biochem. 226, 1-3.
2. Powis, G. (1994) Signaling pathways as targets for anticancer drugs. Pharmacol. Ther. 62, 57-95.
3. Yaish, P., Gazit, A., Gilon, C. and Levitzki, A. (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-35.
4. Gazit, A., Yaish, P., Gilon, C. and Levitzki, A. (1989) Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32, 2344-52.
5. Yoneda, T., Lyall, R., Alsine, M.M., Pearsons, P.E., Spada, A.P., Levitzki, A., Zilberstein, A. and Mundy, G.R. (1991) The antiproliferative effects of tyrosine kinase inhibitor tyrphostin on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51, 4430-5.
6. Kohl, N.E., Omer, C.A., Conner, M., Anthony, N.J., Davide, J.P., DeSolms, S., Giuliani, E.A., Kral, A.M., Miller, P., Mosser, S.D., O'Neil, T., Rands, E., Schaber, M.D., Gibbs, J.B and Olif, A. (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinoma in ras transgenic mice. Nature Med. 1, 792-7.
7. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leader, S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A. and Roifman, C.M. (1996) Inhibition of recurrent human pre-B acute lymphoblastic leukemia by Jak-2 tyrosine kinase inhibitor. Nature.
8. Tsai, C.M., Levitzki, A., Wu, L.H., Chang, K.T., Chen, J.U., Cheng, C.C., Gazit, A. and Peng, R.P. (1996) Enhancement of chemosensitivity by tyrphostin AG 825 in high p185neu expressing non-small cell lung cancer cells. Cancer Res. 56, 1068-74.
9. Besalga, J., Norton, L., Massui, H., Papdilla, A., Caplar, K. and Miller, W.H. (1993) Receptor blockade with monoclonal antibodies as anti-cancer therapy. J. Natl. Cancer Inst. 85, 1327-33.
10. Ekstrand, A.J., Sugawa, N., James, C.D. and Collins, V.P. (1992) Amplified and rearranged epidermal growth factor receptors genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 89, 4309-13.
11. Rajan, R., Vanderslice, R., Kapur, S., Lynch, J., Thompson, R. and Djakiew, D. (1996) Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28, 1-9.
12. Myers, R.B., Kudlow, J.E. and Grizzle, W.E. (1993) Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod. Pathol. 6, 733-7.
13. Han, Y., Caday, C.G., Nanda, A., Cavenee, W.K. and Huang, H.J. (1996) Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 56, 3859-61.
14. Press, M.F., Jones, L.A., Godolphin, W., Edwards, C.L. and Slamon, D.J. (1990) HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog. Clin. Biol. Res. 354A, 209-21.
15. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.I., Ullrich, A. and McGuire, W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-82.
16. Heldin, C.H. and Westermark, B. (1991) Platelet-derived growth factor and autocrine mechanisms of oncogenic processes. CRC Crit. Rev. Oncog. 2, 109-24.
17. Gazit, A., Osherov, N., Posner, I., Bar-Sinai, A., Gilon, C. and Levitzki, A. (1993) Tyrphostin 3. Structure activity relation-ship studies of 5-S-Aryl α-substituted Benzylidenemalononitrile Tyrphostins. J. Med. Chem. 36, 3556-64.
18. Gazit, A., App, H., McMahon, G., Chen, J., Levitzki, A. and Bohmer, F.D. (1996) Tyrphostins 5.-Potent Inhibitors of PDGF receptor tyrosine kinase. SAR in Quinixalines, Quinolines and Indole tyrphostins. J. Med. Chem., 39, 2170-7.
19. Kovalenko, M., Gazit, A., Bohmer, A., Rorsman, L., Ronnstrand, J., Heldin, C.H., Waltenberger, J., Bohmer, F.D. and Levitzki, A. (1994) Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54, 6106-14.
20. Levitzki, A. (1996) SRC as a target for anti-cancer drugs. Anti Cancer Drug Design 11, 175-82.
21. Strawn, L.M., McMahon, G., App, H., Schreck, R., Kuchler, W.R., Longhi, M.P., Hui, T.H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Ken, G., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, P. and Shawver, L.K. (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-5.
22. Martiny-Baron, G. and Norme, D. (1995) VEGF mediated tumor angiogenesis: a new target for cancer therapy. Curr. Op. Biotech. 6, 675-80.
23. Indolfi, C., Avidimento, E.V., Papacciuolo, A., Di Lorenzo, E., Esposito, G., Stabile, E., Felicielo, A., Mele, E., Giuliano, P., Gindorelli, G.L. and Chiariell, M. (1995) Inhibition of cellular ras prevents smooth muscle proliferation after vascular injury in vivo. Nature Med. 1, 541-5.
24. Dudley, T.D., Pang, L., Decker, S.J., Bridges, A.J. and Saltiel, A. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686-9.
25. Vesely, J., Havlicek, L., Strand, M., Blow, J.J., Donlla-Deana, A., Pinna, L., Letham, D.S., Kato, J., Detvaud, L. and Lederc, S. (1994) Inhibition of cyclin dependent kinases by purine analogs. Eur. J. Biochem. 224, 771-86.
26. Losiewicz, M.D., Carlson, B.A., Kaur, G., Sausville, E.A. and Worland, P.J. (1994). Potent inhibition of cdc2 kinase by the flavanoid L86-8275. Biochem. Biophys. Res. Commun. 201, 589-95.
27. Prendville, J., Crowther, D., Thatcher, N., Woll, P.J., Fox, B.W., McGown, G., Testa, N., McDermott, R. and Potter, M. (1994) A phase I study of intravenous bryostatin 1 in patients with advanced cancer. J. Cell. Physiol. 155, 301-12.
28. Hanke, J.H., Gardner, J.P., Dow, R.L., Changelian, P.S., Erissette, W.H., Weringer, E.J., Pollok, B.A. and Connelly, P.A. (1996) Discovery of a novel potent and src family-selective tyrosine kinase Inhibitor. J. Biol. Chem. 271, 695-701.
29. Barker, A.J. (1995) Quinazoline derivatives and their use as anti-cancer agents.
30. Osherov, N. and Levitzki, A. (1994) Epidermal growth factor dependent activation of Src family kinases. Eur. J. Biochem. 225, 1047-53.
31. Fry, D.W., Kraker, A.J., McMichael, A., Ambroso, L.A., Nelson, J.M., Leopold, W.R., Connors, R.W. and Bridges, A.J. (1994) A specific inhibitor of the epidermal growth factor receptor tyrosinc kinase. Science 9, 1093-5.
32. Buchdunger, E., Trinks, U., Mett, H., Regenass, U., Muller, M., Meyer, T., McGlynn, E., Pinna, L.A., Traxler, P. and Lydon, N.G. (1994) 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo and tumor activity. Proc. Natl. Acad. Sci. USA 91, 2334-8.
33. Levitzki, A. and Gazit, A. (1995) Tyrosine kinases inhibition: An approach to drug development. Science 267, 1782-8.
34. Osherov, N., Gazit, A., Gilon, C. and Levitzki, A. (1993) Selective inhibition of the EGF and HER2/Neu receptors by tyrphostins. J. Biol. Chem. 268, 11134-42.
35. Shepard, H.M., Lewis, G.D., Sarup, J.C., Frendly, B.M., Maneval, D., Mordenti, J., Figari, I., Kotts, C.E. and Palladino, M.A.J. (1991) Monoclonal antibody therapy of human cancer: taking the HER-2 protooncogene to the clinic. J. Clin. Immunol. 11, 117-27.
36. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Regenass, U. and Lydon, N.B. (1995) Selective inhibition of the platelet derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimideine class. Proc. Natl. Acad. Sci. USA 28, 2558-62.
37. Anafi, M., Ben-Neriah, Y. and Levitzki, A. (1993) Tyrphostins induce differentiation of mouse erythroleukemia cells. FEBS Lett. 330, 260-4.
38. bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs 5, 213-22.
39. Choo, Y., Sanchez-Garcia, I. and Klug, A. (1994) In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 372, 642-645.
40. Shore, S.K., Nabissa, P.M. and Reddy, E.P. (1993) Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein kinase activity. Oncogene 8, 3183-8.
41. Love, R.R. and Korolchouk, V. (1993) Tamoxifen therapy in breast cancer worldwide. Bull. Wld. Hlth. Organ. 71, 795-803.
42. Wakeling, A.E., Dukes, M. and Bowler, J. (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867-73.
43. Besalga, J. and Mendelson, J. (1994) Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol. Ther. 64, 127-54.
44. Uckun, F.M., Evans, W.E., Forsyth, C.J., Waddick, K.G., Ahlgren, L.T., Chelstrom, L.M., Burkhrdt, A., Bolen, J. and Myers, D.E. (1995) Biotherapy of B-cell precursor leukemia by targeting genistein to CD19, associated tyrosine kinases. Science 10, 886-91.
45. Ross, R.C. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990's. Nature 302, 801-9.
46. Bryckaert, M.C., Eldor, A., Gazit, A., Osherov, N., Gilon, C., Fontenay, M., Levitzki, A. and Tobelem, G. (1992) Inhibition of platelet derived growth factor (PDGF) induced mitogenic activity by PDGF receptor tyrosine kinase tyrphostin inhibitors. Exp. Cell Res. 199, 255-61.
47. Golomb, G., Fishbein, I., Banai, S., Mishaly, D., Moscovitz, D., Gertz, A., Gazit, A. and Levitzki, A. (1996) Controlled delivery of a tyrphostin inhibits intimal hyperplasia in rat carotid artery injury. Atherosclerosis 125, 171-82
48. Elder, J.T., Fisher, G.J., Lindquist, P.B., Bennet, G.L., Pittelkow, M.R., Goffey, R.J., Elliysworth, L., Derynk, R. and Voorhees, J.J. (1989) Overexpression of TGFa in psoriatic epidermis. Science 243, 670-5.
49. Ben-Bassat, H., Vardi, D.V., Gazit, A., Klaus, S.N., Chaouat, M., Hartzstark, Z. and Levitzki, A. (1995) Tyrphostins suppress the growth of psoriatic keratinocytes. Exp. Dermatol. 4, 82-4.
50. Dyson, N., Howley, P.M., Munger, K. and Harlow, E. (1989) The human Papillomavirus-16 E7 is able to bind the retinoblastoma gene product. Science 243, 934-7.
51. Werness, B.A., Levine, A.J. and Howley, P.M. (1990) Association of human papilloma virus type 16 and 18 with p53. Science 248, 934-7.
52. Auewarakul, P., Gissmaa, L. and Cid-Arregui, A. (1994) Targeted expression of the E6 and E7 oncogenes of human papilloma virus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol. Cell. Biol. 14, 8250-8.
53. Ben-Bassat, H. (1997) Blockers of EGF receptor and the cell cycle induce growth arrest, differentiation and apoptosis in HPV 16 immortalized human keratinocytes. Cancer Res. (in press).
54. Boss, J.L. (1989) Ras oncogenes and human cancer. Cancer Res. 49, 4682-9.
55. Stepp-Lorenzino, L., Zhenping, M., Rands, E., Kohl, N.E., Gibbs, J.B., Oliff, A. and Rosen N. (1995) A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res. 55, 5302-9.
56. Segal, M., Willumsen, B.M. and Levitzki, A. (1993) Residues crucial for Ras interaction with GDP-GTP exchangers. Proc. Natl. Acad. Sci. USA 90, 5564-8.
57. Symons, M. (1995) The Roc Rho pathways as a source for drug targets for Ras-mediated malignancies. Curr. Op. Biotech. 6, 668-74.
58. Cordon-Cardo, C. (1995) Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 147, 545-60.
59. Osterov, N. and Levitzki, A. (1997) Tyrphostin AG 494 blocks Cdk2 activation. FEBS lett. 410, 187-190.
60. Kleinberger-Doron, N and Levitzki, A. (1997) Inhibition of Cdk2 activation by selected tyrphostins cause cell cycle arrest in late G1 and S (submitted).
61. WAF1 and proliferating cell nuclear antigen. Curr. Biol. 1, 275-82.
62. Koizumi, M., Kamiya, H. and Ohtsuka, E. (1992) Ribozymes designed to inhibit transformation of MH 3T3 cells by the activated c-Ha-ras gene. Gene 17, 179-84.
63. Sirois, M.G., Simons, M. and Edelman, E.R. (1996) Antisense oligonucleotide inhibition of PDGFR-β Receptor subunit expression directs suppression of intimai thickening.